Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study

This nonrandomized, open-label, multi-cohort Phase 1b study (NCT02779751) investigated the safety and efficacy of abemaciclib plus pembrolizumab with/without anastrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Rugo, Hope S., Kabos, Peter, Beck, J. Thad, Jerusalem, Guy, Wildiers, Hans, Sevillano, Elena, Paz-Ares, Luis, Chisamore, Michael J., Chapman, Sonya C., Hossain, Anwar M., Chen, Yanyun, Tolaney, Sara M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637121/
https://www.ncbi.nlm.nih.gov/pubmed/36335120
http://dx.doi.org/10.1038/s41523-022-00482-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637121/
https://www.ncbi.nlm.nih.gov/pubmed/36335120
http://dx.doi.org/10.1038/s41523-022-00482-2

Ejemplares similares